Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California. more
Time Frame | TARS | Sector | S&P500 |
---|---|---|---|
1-Week Return | 5.15% | -3.39% | 0.2% |
1-Month Return | 19.34% | -1.92% | 2.72% |
3-Month Return | 71.53% | -10.54% | 7.31% |
6-Month Return | 84.67% | -4.47% | 10.44% |
1-Year Return | 180.61% | 4.06% | 27.53% |
3-Year Return | 106.51% | 0.94% | 30.88% |
5-Year Return | 158.79% | 36.67% | 89.21% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | 33.43M | 57.03M | 25.82M | 17.45M | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":58.62,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":45.27,"profit":true},{"date":"2023-12-31","value":30.59,"profit":true}] |
Cost of Revenue | 74.00K | 246.00K | 2.08M | 955.00K | 1.59M | [{"date":"2019-12-31","value":3.57,"profit":true},{"date":"2020-12-31","value":11.86,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":46.02,"profit":true},{"date":"2023-12-31","value":76.77,"profit":true}] |
Gross Profit | (74.00K) | (246.00K) | 54.95M | 24.86M | 15.85M | [{"date":"2019-12-31","value":-0.13,"profit":false},{"date":"2020-12-31","value":-0.45,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":45.24,"profit":true},{"date":"2023-12-31","value":28.85,"profit":true}] |
Gross Margin | - | (0.74%) | 96.36% | 96.30% | 90.87% | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-0.76,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":99.94,"profit":true},{"date":"2023-12-31","value":94.3,"profit":true}] |
Operating Expenses | 4.30M | 27.00M | 67.11M | 87.57M | 159.01M | [{"date":"2019-12-31","value":2.7,"profit":true},{"date":"2020-12-31","value":16.98,"profit":true},{"date":"2021-12-31","value":42.2,"profit":true},{"date":"2022-12-31","value":55.07,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (4.30M) | (27.00M) | (12.16M) | (62.71M) | (143.16M) | [{"date":"2019-12-31","value":-429800000,"profit":false},{"date":"2020-12-31","value":-2699800000,"profit":false},{"date":"2021-12-31","value":-1215700000,"profit":false},{"date":"2022-12-31","value":-6271200000,"profit":false},{"date":"2023-12-31","value":-14315800000,"profit":false}] |
Total Non-Operating Income/Expense | (411.00K) | 376.00K | (1.58M) | 1.92M | 13.70M | [{"date":"2019-12-31","value":-3,"profit":false},{"date":"2020-12-31","value":2.74,"profit":true},{"date":"2021-12-31","value":-11.52,"profit":false},{"date":"2022-12-31","value":13.99,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (4.67M) | (26.81M) | (13.77M) | (62.09M) | (135.89M) | [{"date":"2019-12-31","value":-466900000,"profit":false},{"date":"2020-12-31","value":-2681000000,"profit":false},{"date":"2021-12-31","value":-1377200000,"profit":false},{"date":"2022-12-31","value":-6209500000,"profit":false},{"date":"2023-12-31","value":-13589300000,"profit":false}] |
Income Taxes | 1.00K | 1.00K | 55.00K | (4.00K) | 709.11K | [{"date":"2019-12-31","value":0.14,"profit":true},{"date":"2020-12-31","value":0.14,"profit":true},{"date":"2021-12-31","value":7.76,"profit":true},{"date":"2022-12-31","value":-0.56,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Income After Taxes | (4.67M) | (26.81M) | (13.83M) | (62.09M) | (136.60M) | [{"date":"2019-12-31","value":-467000000,"profit":false},{"date":"2020-12-31","value":-2681100000,"profit":false},{"date":"2021-12-31","value":-1382700000,"profit":false},{"date":"2022-12-31","value":-6209100000,"profit":false},{"date":"2023-12-31","value":-13660210500,"profit":false}] |
Income From Continuous Operations | (4.67M) | (26.81M) | (13.83M) | (62.09M) | (107.59M) | [{"date":"2019-12-31","value":-467000000,"profit":false},{"date":"2020-12-31","value":-2681100000,"profit":false},{"date":"2021-12-31","value":-1382700000,"profit":false},{"date":"2022-12-31","value":-6209100000,"profit":false},{"date":"2023-12-31","value":-10759000000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (4.67M) | (26.81M) | (13.83M) | (62.09M) | (135.89M) | [{"date":"2019-12-31","value":-467000000,"profit":false},{"date":"2020-12-31","value":-2681100000,"profit":false},{"date":"2021-12-31","value":-1382700000,"profit":false},{"date":"2022-12-31","value":-6209100000,"profit":false},{"date":"2023-12-31","value":-13589300000,"profit":false}] |
EPS (Diluted) | - | (4.58) | (0.68) | (2.55) | (4.64) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-458.49,"profit":false},{"date":"2021-12-31","value":-68,"profit":false},{"date":"2022-12-31","value":-255,"profit":false},{"date":"2023-12-31","value":-464,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
TARS | |
---|---|
Cash Ratio | 4.81 |
Current Ratio | 5.42 |
Quick Ratio | 5.38 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
TARS | |
---|---|
ROA (LTM) | -27.26% |
ROE (LTM) | -59.56% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
TARS | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.37 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.63 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
TARS | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 15.26 |
P/B | 8.33 |
Price/FCF | NM |
EV/R | 13.37 |
EV/Ebitda | NM |
Tarsus Pharmaceuticals Inc (TARS) share price today is $54.085
Yes, Indians can buy shares of Tarsus Pharmaceuticals Inc (TARS) on Vested. To buy Tarsus Pharmaceuticals Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in TARS stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Tarsus Pharmaceuticals Inc (TARS) via the Vested app. You can start investing in Tarsus Pharmaceuticals Inc (TARS) with a minimum investment of $1.
You can invest in shares of Tarsus Pharmaceuticals Inc (TARS) via Vested in three simple steps:
The 52-week high price of Tarsus Pharmaceuticals Inc (TARS) is $54.44. The 52-week low price of Tarsus Pharmaceuticals Inc (TARS) is $18.99.
The price-to-earnings (P/E) ratio of Tarsus Pharmaceuticals Inc (TARS) is
The price-to-book (P/B) ratio of Tarsus Pharmaceuticals Inc (TARS) is 8.33
The dividend yield of Tarsus Pharmaceuticals Inc (TARS) is 0.00%
The market capitalization of Tarsus Pharmaceuticals Inc (TARS) is $1.98B
The stock symbol (or ticker) of Tarsus Pharmaceuticals Inc is TARS